Vydiant, Inc

What Vydiant, Inc does

Vydiant, Inc. is a U.S.-based precision health technology company that has built the OneHealth Digital Vaccine platform — an intelligence layer combining machine learning with human expert curation across 44 million+ peer-reviewed studies, 9,400+ directional health relationships, 5,000+ lifestyle factors, and 154,000+ diseases/conditions — to deliver evidence-ranked, pathway-level intervention guidance calibrated to an individual's genetics, biomarkers, wearable data, environment, cultural context, and pharmaceutical regimen. Its flagship clinical product, PathWise PRS, performs polygenic risk scoring across five biological systems (metabolic, cardiovascular, cognitive, inflammatory, and cellular), is ordered through physicians, and surfaces outputs through both a provider portal and a patient-facing dashboard featuring the 1Health Score and Pathway Resilience Profile. The platform exposes FHIR-compatible, EHR-integrated APIs so clinical intelligence can be embedded inside existing provider workflows without new infrastructure, and it integrates with wearable devices and continuous glucose monitors for real-time biological input.

The company operates a multi-stream revenue model: (1) physician-ordered PathWise PRS clinical testing monetized through Basic Service (free limited), Personal Premium, and Business Premium subscription tiers; (2) enterprise licensing of OneHealth Explore to pharmaceutical, food, and research partners to reduce early-stage research costs; and (3) value-based care contracts with health systems built around prevention-outcome documentation. Vydiant reports $3M+ in revenue sourced from named major food and pharmaceutical partners including GSK, Ferrero, and Campbell's, alongside relationships with the U.S. Department of Veterans Affairs, UC Davis, the U.S. Pharmacopeia, the University of Wisconsin Food Science department, and others. The asset is defended by six issued patents, a compounding data flywheel (1M+ new peer-reviewed papers integrated annually), HIPAA compliance, and ISO/IEC 27001:2013 certification. Founded by a former Director of the FDA's Division of Personalized Nutrition and Medicine and led by Chairman/CEO Terry Carlone, JD, with CSO Jim Kaput, PhD, Vydiant positions itself as a precision prevention platform addressing the estimated 80% of U.S. healthcare spend tied to preventable chronic disease.

Vydiant, Inc. is a U.S.-based precision health technology company that has built the OneHealth Digital Vaccine platform, an AI-augmented intelligence layer combining machine learning with human expert curation across 44 million+ peer-reviewed studies to deliver evidence-ranked, pathway-level intervention guidance calibrated to individual genetics, biomarkers, lifestyle, environment, and pharmaceutical regimen. Its flagship clinical product, PathWise PRS, performs polygenic risk scoring across five biological systems and is distributed through physician ordering with separate provider and patient portals, embedding via FHIR-compatible EHR APIs into existing clinical workflows. The company generates revenue from PathWise PRS subscriptions (Basic, Personal Premium, Business Premium tiers), enterprise licensing of OneHealth Explore to pharmaceutical, food, and research partners, and value-based care contracts with health systems, reporting $3M+ revenue with named partners including GSK, Ferrero, Campbell's, and the U.S. Department of Veterans Affairs. Six issued patents, ISO/IEC 27001:2013 certification, and a founding team with FDA and Nestlé scientific pedigree support a positioning in precision prevention against the 80% of U.S. healthcare spend tied to preventable chronic disease.

Name

Vydiant, Inc

Legal name

Vydiant, Inc.

Website

https://vydiant.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Vydiant is a precision health technology company whose OneHealth Digital Vaccine platform analyzes 44M+ peer-reviewed studies to deliver evidence-ranked, pathway-level intervention guidance. It serves physicians via the PathWise PRS clinical product and licenses OneHealth Explore to pharmaceutical, food, and research partners.

Ownership category

akta.pro rank

Product category

Clinical Decision Support Software

NAICS

Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

akta.pro secondary industries

Condition-specific Digital Therapeutics (DTx) (HLACANAA), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG), DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)

Keywords

• Precision prevention platform
• Polygenic risk scoring
• Digital vaccine platform
• Clinical decision support
• Pathway-based genetics

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. PathWise PRS Clinical Testing: Physician-ordered genetic testing with cheek swab sample collection. Results delivered to physicians in 4-6 weeks with clinical interpretation reports and patient dashboard access.
2. Premium Service Subscriptions: Subscription-based tiers including Basic Service (limited functionality) and Premium Services with differing functionality based on subscription level. Auto-renewal with monthly or annual billing.
3. Enterprise Research Partnerships: Revenue from pharma, food, and research partners using OneHealth Explore platform for research cost reduction. Described as proven revenue from major food and pharmaceutical companies.
4. Health System Value-Based Care Contracts: Revenue from health systems and clinical leadership through prevention outcome documentation supporting VBC contract performance.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Vydiant operates the OneHealth Digital Vaccine Platform, an AI/ML intelligence layer that integrates 44 million peer-reviewed studies with individual patient biology, biomarkers, lifestyle, environment, and pharmaceutical interactions to deliver personalized, evidence-ranked intervention guidance. Its flagship commercial product, PathWise PRS, is a physician-ordered, pathway-based polygenic risk scoring test that identifies which biological systems drive a patient's risk and which intervention will work for that specific patient. The company also offers OneHealth Explore as a research platform for pharma, food, and research partners.

Product overview

Vydiant offers the OneHealth Digital Vaccine Platform as its core intelligence system, which analyzes 44 million peer-reviewed studies to power precision prevention. The primary consumer-facing product is PathWise PRS (Polygenic Risk Scores), a pathway-based genetic risk scoring platform that identifies biological systems driving patient risk and delivers evidence-ranked, personalized intervention guidance. The platform includes patient-facing features like the 1Health Score and Pathway Resilience Profile accessible through a patient dashboard. For pharmaceutical, food, and research partners, OneHealth Explore enables knowledge retrieval from scientific literature. All products share a common intelligence core with compounding data across the ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

• PathWise PRS: PathWay-Based Precision Health Platform providing pathway analysis across 5 biological systems with clinical-grade analysis and physician-guided care.
• OneHealth
• 1Health Score
• Accurate Intelligence

Products and services

• PathWise PRS Pathway-based polygenic risk scoring product ordered by physicians that maps a patient's risk across metabolic, cardiovascular, cognitive, inflammatory, and cellular systems and returns evidence-ranked, personalized intervention guidance for clinical decision-making.
• OneHealth Digital Vaccine Platform

Quantifiable outcome

• Early-stage research costs reduced by up to 90% for pharma, food, and research partners using OneHealth Explore
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered major, core and supporting.

• FerreromajorStrategic or Co-development PartnerLogo displayed on Vydiant partner page indicating collaboration with Ferrero (global confectionery and confectionery-based food company) in the nutrition and health space.
• GSK (GlaxoSmithKline)majorStrategic or Co-development PartnerLogo displayed on Vydiant partner page indicating pharmaceutical industry partnership for research and development collaboration.
• IFNA (Institute for Functional Nutrition and Naturopathic Acupuncturists)coreStrategic or Co-development PartnerFeatured partner with dedicated logo placement. Collaboration in functional nutrition education and practice, potentially involving research partnerships.
• Campbell'smajorStrategic or Co-development PartnerLogo displayed indicating food industry research partnership for nutrition science and personalized dietary guidance.
• UC DaviscoreStrategic or Co-development PartnerUniversity of California Davis collaboration in food science research, indicated by logo placement on partner page.
• Concordia PharmacysupportingStrategic or Co-development PartnerPharmacy partnership indicated by logo placement, potentially for medication-gene interaction research and clinical implementation.
• VA (Veterans Affairs)majorStrategic or Co-development PartnerPartnership with Veterans Affairs healthcare system indicated by logo, potentially for precision health implementation across VA system.
• USP (United States Pharmacopeia)supportingTechnology or IntegrationCollaboration with U.S. Pharmacopeia for standards in dietary supplements, medications, and health-related product quality.
• UW-IS Food SciencesupportingStrategic or Co-development PartnerUniversity of Wisconsin Food Science department partnership for nutrition and food science research collaboration.
• Arizona PsychsupportingStrategic or Co-development PartnerPartnership with Arizona psychiatric practice indicated by logo, potentially for cognitive health and mental wellness research.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Color Health: Color offers clinical-grade genetic testing and population health programs integrated with health systems and employers. Directly comparable to Vydiant's PathWise PRS clinical testing and value-based-care contract motion.
• Genomic Prediction: Genomic Prediction builds clinical polygenic risk scoring and pathway-based genetic testing. Closely aligned with Vydiant's pathway-level PRS approach and algorithmic endpoint positioning.
• Helix: Helix operates a DNA sequencing platform powering population genomics and health-system programs. Comparable as a clinical-genomics infrastructure and SaaS-style platform serving health systems and partners.

Emerging players

• Function Health: Function Health offers a comprehensive precision-prevention membership combining diagnostics, wearables, and clinician review. Comparable to Vydiant's consumer subscription + clinical intelligence positioning in precision prevention.
• InsideTracker: InsideTracker delivers biomarker-driven, personalized health guidance via a subscription platform. Comparable to Vydiant's evidence-ranked intervention guidance and consumer health dashboard.
• Viome: Viome combines microbiome and molecular testing with AI-driven nutrition recommendations. Comparable to Vydiant's pathway-level intervention guidance integrating multi-omic and lifestyle data.

Broad incumbents

• 23andMe: 23andMe is a consumer genetic testing platform with a therapeutics pipeline and large genomic database. Comparable as a broad incumbent in genetic testing and personalized health, though less focused on pathway-level intervention guidance.
• Tempus: Tempus is an AI-driven precision medicine company with genomics, clinical data, and pharma R&D partnerships. Comparable as a broad incumbent in AI-powered precision health and pharma-licensing motion.
• Natera: Natera is a clinical genetic testing company serving oncology, reproductive health, and organ transplantation. Comparable as a broad incumbent in clinical genomics with health-system sales channels.
• Verily (Alphabet): Verily is Alphabet's precision health subsidiary combining data, devices, and clinical research at scale. Comparable as a broad incumbent in evidence-driven precision prevention and pharma research enablement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vydiant
• Xx.com/vydiant

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vydiant, Inc